Enlarge / Moderna CEO Stephane Bancel throughout a Bloomberg Tv interview on the closing day of the World Financial Discussion board in Davos, Switzerland, on Could 26, 2022. (credit score: Getty | Jason Alden)

Issues are trying rosy for Moderna, because it reported sudden first-quarter earnings Thursday. However the firm shouldn’t be wavering in its plans to dramatically hike the value of its COVID-19 vaccines.

Whereas monetary analysts anticipated the corporate to submit income of $1.18 billion and a lack of $1.77 per share within the first quarter, the corporate reported $1.86 billion in income with a small revenue of 19 cents per share.

The corporate forecasts $5 billion in COVID vaccine gross sales for this 12 months.